Previous studies demonstrated that
zolmitriptan at doses of 1 to 25 mg was highly effective in treating acute
migraine attacks. The 2.5-mg dose had a favorable
therapeutic effect with high efficacy and good tolerability. The objective of this study was to further evaluate the efficacy of a single 2.5-mg dose of
zolmitriptan (
Zomig, formerly known as
311C90) for acute treatment of a single moderate or severe
migraine attack. The study was a randomized, double-blind, placebo-controlled clinical trial. Female and male patients, 12 to 65 years old, with
migraine (with or without
aura) for > or = 1 year, one to six
migraines per month, and age at onset < 50 years were included; 327 patients were screened and randomized to receive either
zolmitriptan (n = 219) or placebo (n = 108). Patients treated a single moderate or severe
migraine headache with 2.5 mg
zolmitriptan or placebo and recorded clinical efficacy and adverse events on a diary form.
Headache response at 2 hours was 62% for
zolmitriptan compared with 36% for placebo (p < 0.001); at 4 hours,
headache response was 70% with
zolmitriptan and 37% with placebo (p < 0.001).
Headache recurrence in patients treated with 2.5 mg
zolmitriptan was 22% (versus placebo 30%). The
headache response at 4 hours,
pain-free rate, and response rate of nonheadache symptoms favored
zolmitriptan over placebo. No serious adverse events were associated with
zolmitriptan treatment. A 2.5-mg dose of
zolmitriptan is clinically effective and well tolerated for the acute treatment of
migraine.